Triptorelin Acetate
GnRH analog
A synthetic decapeptide GnRH agonist referenced in reproductive-research literature.
Overview
Triptorelin is a synthetic decapeptide agonist analog of gonadotropin-releasing hormone (GnRH), in which a D-tryptophan substitution at position 6 increases potency and duration. It is marketed under names such as Trelstar and Decapeptyl.
At a glance
What Triptorelin Acetate does
Triptorelin is a long-acting GnRH agonist — a synthetic GnRH analogue with a D-tryptophan substitution at position 6 that greatly increases receptor-binding affinity and resistance to breakdown, so it occupies the pituitary GnRH receptor for hours instead of the seconds native GnRH lasts. What it does is best understood as biphasic. In the first roughly one to two weeks it acts as a potent agonist, over-stimulating pituitary gonadotrophs and producing a transient surge — the 'flare' — in LH, FSH, and consequently testosterone or estradiol.
With continued exposure, the persistent, non-pulsatile receptor occupancy causes the gonadotrophs to downregulate and desensitize their GnRH receptors. After about two to four weeks, LH and FSH fall sharply, and downstream sex-steroid output (testosterone in men, estradiol in women) drops to castrate or postmenopausal levels. This 'medical castration' through paradoxical suppression is the therapeutic goal in most of its uses.
Because of this profile, triptorelin's studied and clinical actions revolve around profound, reversible gonadal-axis suppression: it is used in hormone-sensitive prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and to prevent premature LH surges in assisted reproduction. The transient flare is clinically relevant — for example, prostate-cancer regimens often anticipate and manage it. Evidence here is human and clinical; the biphasic flare-then-suppression pharmacodynamics are well characterized.
Effects reported in research
- Produces an initial 'flare' surge in LH, FSH, and sex steroids during the first 1-2 weeks of dosing (human clinical, well documented).
- After ~2-4 weeks of continuous exposure, downregulates and desensitizes pituitary GnRH receptors, sharply lowering LH and FSH (human).
- Suppresses testosterone to castrate levels in men, exploited in hormone-sensitive prostate cancer (human clinical use).
- Suppresses estradiol to postmenopausal levels in women, used in endometriosis and uterine fibroids (human clinical use).
- Halts pathologically early puberty in central precocious puberty (human clinical use).
- Prevents premature LH surges during controlled ovarian stimulation in assisted reproduction (human clinical use).
- Its effects are reversible: the axis recovers after the drug is discontinued (human).
- Longer receptor residence than native GnRH (hours vs. seconds) underlies its ability to drive continuous, suppressive stimulation (pharmacology).
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
Triptorelin is a GnRH receptor superagonist; the D-Trp6 substitution enhances receptor affinity and metabolic stability. Acute administration transiently stimulates LH and FSH release, but sustained (continuous) exposure downregulates and desensitizes pituitary GnRH receptors, suppressing gonadotropin and downstream sex-steroid production. This 'medical castration' effect underlies its use in hormone-sensitive conditions.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which Triptorelin Acetate appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- Long-acting GnRH superagonist with a D-Trp6 substitution.
- Initial flare of LH/FSH followed by sustained receptor downregulation.
- Net effect is suppression of sex-steroid production with continuous dosing.
- Approved for prostate cancer, endometriosis, and precocious puberty.
- Contrasts with native short-acting gonadorelin.
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. Triptorelin Acetate is a research compound.
Reference figures only. Clinical/research use spans low-microgram daily or single subcutaneous doses (IVF down-regulation, acute stimulation) and multi-milligram depot formulations (sustained suppression).
- IVF down-regulation / acute research: ~0.1 mg subcutaneous daily, or single sub-milligram doses referenced
- Depot suppression formulations: ~3.75 mg (monthly), 11.25 mg (3-month), 22.5 mg (6-month)
Expect an initial hormonal flare before suppression; salt form matters (base ~1311 Da vs pamoate ~1700 Da). Reference figures for research context only.
How it compares
Triptorelin is a modified long-acting GnRH superagonist that suppresses the axis via receptor downregulation, opposite to the physiological stimulation from pulsatile native gonadorelin.
Commonly studied alongside
Compounds frequently researched together with Triptorelin Acetate in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
Triptorelin Acetate sits in the Hormonal & Sexual Health area of the PeptiDex library.
- Entry type: Research compound reference
- Browse the full library →
- Glossary of terms →
Where researchers source Triptorelin Acetate
For researchers studying Triptorelin Acetate, third-party suppliers such as Practically Natty Peptides offer research-grade material with third-party Certificates of Analysis and US-based shipping.
PeptiDex does not maintain a direct supplier listing for this compound. The link above goes to a third-party research-supplier directory.
Frequently asked questions
What is triptorelin?
Triptorelin is a synthetic GnRH (gonadotropin-releasing hormone) super-agonist, a decapeptide analog of gonadorelin with D-tryptophan substituted at position 6. That substitution increases receptor affinity and resistance to enzymatic breakdown, giving it far greater potency and duration than native GnRH.
How does triptorelin affect the HPG axis?
An initial dose causes a transient flare of LH, FSH and sex-hormone release, but sustained or depot exposure desensitizes and downregulates pituitary GnRH receptors, producing profound downstream suppression of LH/FSH and sex hormones. It is studied in reproductive endocrinology and hormone-suppression models.
How does triptorelin differ from gonadorelin?
Gonadorelin is native GnRH with a very short half-life used for pulsatile stimulation, whereas triptorelin is a long-acting super-agonist whose continuous presence ultimately suppresses the axis. The practical difference is stimulation (gonadorelin) versus flare-then-suppression (triptorelin).
What are triptorelin's half-life and depot forms?
As the free peptide it has a terminal half-life of roughly 3 hours after IV dosing, but subcutaneous and especially depot (microsphere/pamoate) formulations extend release to weeks or months. Depot products (e.g. 1-, 3- and 6-month formulations) are used clinically in hormone-suppression indications.
Is triptorelin an approved drug?
Yes. Triptorelin (e.g. Trelstar, Triptodur, Decapeptyl) is an approved GnRH-agonist pharmaceutical used in indications such as advanced prostate cancer and central precocious puberty, and in IVF down-regulation protocols. Research-chemical supply of the peptide is a separate, non-pharmaceutical channel.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.